Get the Stockscreener App
4.26
0.24%
0.010
Eledon Pharmaceuticals Inc Stock (ELDN) Latest News
Eledon Pharmaceuticals (NASDAQ:ELDN) Earns “Buy” Rating from HC Wainwright - Defense World
HC Wainwright Has Negative Outlook for ELDN Q4 Earnings - Defense World
HC Wainwright Issues Pessimistic Forecast for ELDN Earnings - MarketBeat
Eledon Pharmaceuticals retains shares target, Buy rating on clinical trial progress - Investing.com Nigeria
Eledon Pharmaceuticals retains shares target, Buy rating on clinical trial progress By Investing.com - Investing.com South Africa
Eledon Pharmaceuticals (NASDAQ:ELDN) Given Buy Rating at HC Wainwright - MarketBeat
FY2024 EPS Estimates for ELDN Boosted by Cantor Fitzgerald - MarketBeat
Lifesci Capital Issues Optimistic Outlook for ELDN Earnings - MarketBeat
ARMISTICE CAPITAL, LLC Acquires Shares in Eledon Pharmaceuticals Inc - GuruFocus.com
Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) market cap dropped US$48m last week; individual investors who hold 57% were hit as were institutions - Yahoo Finance
Institutions along with individual investors who hold considerable shares inEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) come under pressure; lose 16% of holdings value - Simply Wall St
Hopkins alum leads Eledon Pharmaceuticals in breakthrough diabetes tegoprubart treatment - Johns Hopkins News-Letter
Eledon Pharmaceuticals Reports Strong Q3 2024 Results - TipRanks
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results - The Manila Times
Eledon Pharma Surges: $85M Offering, Strong Trial Results Drive Q3 Success | ELDN Stock | ELDN Stock News - StockTitan
Amyotrophic Lateral Sclerosis Treatment Market to Grow by USD 663.7 Million from 2024-2028, as Rising Incidence Drives Demand with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve
Midday Stock Roundup: Indie Semiconductor Up 43% - Orange County Business Journal
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference - The Manila Times
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation - The Bakersfield Californian
Eledon Pharmaceuticals CEO to Present at Guggenheim's First Healthcare Innovation Conference | ELDN Stock News - StockTitan
RA Capital Management, L.P. Acquires New Stake in Eledon Pharmac - GuruFocus.com
Biotechnology Value Fund L P's Strategic Acquisition in Eledon P - GuruFocus.com
ELDN stock touches 52-week high at $4.13 amid robust gains - Investing.com Australia
ELDN stock touches 52-week high at $4.13 amid robust gains By Investing.com - Investing.com South Africa
SEC Form 424B5 filed by Eledon Pharmaceuticals Inc. - Quantisnow
Eledon drug helps transplants 'cure' type 1 diabetes - pharmaphorum
Eledon Pharmaceuticals sets terms for $85 million stock offering By Investing.com - Investing.com South Africa
Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart (ELDN) - Seeking Alpha
Eledon Pharmaceuticals Shares Hit 52-Week High After Positive Trial Data - MarketWatch
Promising results for diabetes treatment with new drug By Investing.com - Investing.com Australia
Eledon Pharmaceuticals sets terms for $85 million stock offering - Investing.com India
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine - The Manila Times
Promising results for diabetes treatment with new drug - Investing.com India
Eledon Pharmaceuticals Announces Pricing of $85 Million - GlobeNewswire
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - StockTitan
Algorae Pharmaceuticals Plans Major Securities Issuance - MSN
Amyotrophic Lateral Sclerosis Treatment Market to hit USD 1.1 billion by 2032, says Global Market Insights Inc. - GlobeNewswire
ELDN stock soars to 52-week high, touches $3.35 amid surge - Investing.com
Financial Analysis: Eledon Pharmaceuticals (NASDAQ:ELDN) & ABVC BioPharma (NASDAQ:ABVC) - Defense World
IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, - openPR
IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, Pipeline, Medication, Therapies, Treatment Market and Companies by DelveInsight - Barchart
Eledon Pharmaceuticals completes $4 million equity sale - Investing.com India
Eledon Pharmaceuticals completes $4 million equity sale By Investing.com - Investing.com South Africa
Nantahala Capital Management LLC Invests $1.58 Million in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
Nantahala Capital Management LLC Acquires New Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - MarketBeat
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Update - MarketBeat
Midday Stock Roundup: STAAR Surgical CO. Shares Surge 22% - Orange County Business Journal
Eledon Pharmaceuticals initiates $75 million stock sale agreement By Investing.com - Investing.com Australia
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):